First Patient Dosed In Ph 1/2 Study Of FPI-1966 In Patients With Advanced Solid Tumors Expressing FGFR3
“Dosing of the first patient in this Phase 1/2 study of FPI-1966 demonstrates our continued ability to bring innovative targeted alpha therapies (TATs) into the clinic,” said Chief Executive Officer John Valliant, Ph.D. “This study will evaluate FPI-1966 in patients with solid tumors expressing FGFR3, a validated cancer target found in multiple tumor types with substantial unmet need, notably bladder, ovarian and head and neck cancers. FPI-1966, and the growing number of TATs in our pipeline, are designed as next generation antibody drug conjugates (ADCs) in that they leverage the potency of actinium-225 and alpha particle radiation in place of chemical toxins to selectively eradicate cancer cells. Given the prevalence of the FGFR3 target, and the use of a precision medicine approach that employs an imaging analogue to enable patient selection, we believe FPI-1966 has the potential to become an important new treatment paradigm for cancer patients.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last
